Press coverage about Egalet Corporation (NASDAQ:EGLT) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Egalet Corporation earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 45.4573116895567 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Egalet Corporation (NASDAQ:EGLT) opened at 1.28 on Monday. The firm’s market cap is $33.62 million. The stock’s 50 day moving average price is $1.22 and its 200-day moving average price is $2.68. Egalet Corporation has a 52-week low of $1.01 and a 52-week high of $10.00.

Egalet Corporation (NASDAQ:EGLT) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.10). The firm had revenue of $6.26 million during the quarter, compared to analyst estimates of $6.68 million. Egalet Corporation had a negative net margin of 444.50% and a negative return on equity of 607.49%. Egalet Corporation’s quarterly revenue was up 81.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.97) EPS. On average, analysts forecast that Egalet Corporation will post ($2.75) EPS for the current year.

Several equities research analysts have commented on the stock. Guggenheim set a $7.00 target price on shares of Egalet Corporation and gave the company a “buy” rating in a research note on Monday, August 14th. Stifel Nicolaus reiterated a “buy” rating and issued a $6.00 target price (down from $14.00) on shares of Egalet Corporation in a report on Thursday, August 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price target on shares of Egalet Corporation in a research report on Monday, August 14th. Finally, JMP Securities reduced their price target on shares of Egalet Corporation from $15.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Egalet Corporation has an average rating of “Buy” and a consensus price target of $6.50.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at

About Egalet Corporation

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Insider Buying and Selling by Quarter for Egalet Corporation (NASDAQ:EGLT)

Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.